Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[Q]: The Chiefs took an early lead on a 30-yard pass from Tyler Thigpen to Mark Bradley. The Chiefs defense continued to show improvement in the red zone, limiting the Chargers to two field goals instead of two touch downs. At the end of the first half, Thigpen threw a pass to 34yard touchdown pass to Tony Gonzalez. However, the extra point snap was botched and an attempt at a quick pass failed. The Chargers controlled the second half better than the first, scoring two touchdowns and leading the Chiefs by 7 at the end of the fourth quarter. The Chiefs' final drive ended with a 3-yard touchdown pass to Gonzalez. A 1-point PAT would tie the game. However, Herm Edwards told Thigpen to go for two, explaining in a post-game interview that the defense was too beat up for overtime play. The resulting two-point conversion ended in an incomplete pass. The Chiefs lost by one point.
[A]: Which team won the game?


[Q]: Zeke Bella died on November 17, 2013, from complications due to a stroke, and the injuries received from a fall it induced;
[A]: What was Zeke Bella's cause of death?


[Q]: Riociguat (Adempas(®)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). The drug directly stimulates sGC in a nitric oxide independent manner, thereby increasing the sensitivity of sGC to nitric oxide, leading to increased cyclic guanosine monophosphate generation (a key signalling molecule involved in regulating vascular tone, proliferation, fibrosis and inflammation). Riociguat is the world's first approved pharmacotherapy for CTEPH, with its first global approval in this indication occurring in Canada. It has subsequently been approved in the USA for the treatment of patients with CTEPH and also received its first global approval in patients with PAH in the USA. It is undergoing regulatory review for these indications in Europe and for use in patients with CTEPH in Japan. This article summarizes the milestones in the development of riociguat, leading to its first global approvals in patients with CTEPH and PAH.
[A]:
What is generic name of drug Adempas?